Breast Cancer is associated with high incidents and mortality rates and considered to be the second most frequent type of cancer among women worldwide. One of its invasive modalities is the Triple-Negative subtype. Lacking the expression of ER/PR and HER2 contributes to its severity. Current treatment strategies for TNBC diagnosed patients are believed to be hazardous and do not improve the disease-free survival (DFS) neither the overall survival (OS). Thus, scientist and researchers are seeking alternative remedies that have little or no consequences on the patients. Andrographis paniculate with its remarkable active constituent Andrographolide are attracting the world's attention due to its pharmacological activities against metabolic maladies especially hyperlipidemia, obesity, and diabetes as well as its attribute as an anti-cancer compound. Here, we review the effect of Andrographolide on Triple-Negative Breast Cancer.